Lund University Mapping Study Reveals Epigenetic "On-Off" Switches Controlling Blood Sugar Hormones

Groundbreaking study from Lund University identifies epigenetic patterns that control insulin and glucagon, revealing how the ONECUT2 protein disrupts blood sugar.

By: AXL Media

Published: Apr 24, 2026, 12:23 PM EDT

Source: Information for this report was sourced from Lund University and the journal Nature Metabolism.

Decoding the Cellular "Identity" of the Pancreas

While every cell in the human body carries the same genetic code, their functions are dictated by the epigenome—a system of chemical markers that act as switches to activate or deactivate specific genes. In a landmark study released on April 24, 2026, researchers at Lund University provided the most granular look to date at how these switches operate within the pancreas. The study focused on two critical cell types: beta cells, which produce insulin to lower blood sugar, and alpha cells, which produce glucagon to raise it. This mapping is the first to describe cell-specific epigenetic patterns with such high resolution, revealing how the body’s internal glucose-regulating machinery is hard-wired at a molecular level.

The Role of DNA Methylation in Hormone Regulation

The primary mechanism identified in the study is DNA methylation, a process where small chemical groups attach to DNA to control gene expression without altering the underlying sequence. Professor Charlotte Ling and her team analyzed cells from 24 donors—both with and without type 2 diabetes—to see how these patterns shifted. The team successfully demonstrated that by editing the DNA methylation near the genes for insulin and glucagon in cultured beta cells, they could directly influence hormone production. This discovery marks the first time scientists have pinpointed the exact genomic regions where epigenetic editing could potentially "reset" hormone levels.

A New Culprit in Diabetes: The ONECUT2 Factor

A standout discovery in the research involves a transcription factor known as ONECUT2. The team found that in individuals with type 2 diabetes, ONECUT2 is epigenetically elevated within the beta cells. This elevation creates a devastating domino effect: it impairs the cells' energy production and significantly reduces their ability to release insulin into the bloodstream. By identifying ONECUT2 as a driver of beta cell failure, the study provides a concrete target for future therapies that aim to restore cellular function rather than just managing symptoms.